DBPR108
Modify Date: 2025-08-25 15:33:37
DBPR108 structure
|
Common Name | DBPR108 | ||
|---|---|---|---|---|
| CAS Number | 1186426-66-3 | Molecular Weight | 324.39400 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C16H25FN4O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DBPR108DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9.IC50 value: 15 nM [1]Target: DPP4 inhibitorDBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including inhibition of plasma DPP-IV activity and suppression of blood glucose elevation, were also demonstrated. DBPR108 is a potent, selective, long-acting and safe DPP-IV inhibitor as a potential treatment of type 2 diabetesmellitus. |
| Name | (2S,4S)-4-fluoro-1-[2-[(2-methyl-4-oxo-4-pyrrolidin-1-ylbutan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile |
|---|---|
| Synonym | More Synonyms |
| Description | DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9.IC50 value: 15 nM [1]Target: DPP4 inhibitorDBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including inhibition of plasma DPP-IV activity and suppression of blood glucose elevation, were also demonstrated. DBPR108 is a potent, selective, long-acting and safe DPP-IV inhibitor as a potential treatment of type 2 diabetesmellitus. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C16H25FN4O2 |
|---|---|
| Molecular Weight | 324.39400 |
| Exact Mass | 324.19600 |
| PSA | 76.44000 |
| LogP | 1.09638 |
| Storage condition | 2-8℃ |
| dbpr-108 |
| unii-e329hg23zt |
| DBPR108 |